@article{article, title = {{A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Gu茅rin (BCG) therapy.}},
publisher = {{American Society of Clinical Oncology (ASCO)}},
url = {{}},
year = {{2020}},
month = {{2}},
author = {{Steinberg GD and Palou-Redorta J and Gschwend JE and Tran B and Loriot Y and Daneshmand S and Roupret M and Santiago-Walker AE and Switzky JC and Major C and Baig M et al}},
doi = {{10.1200/jco.2020.38.6_suppl.tps603}},
volume = {{38}},
journal = {{Journal of Clinical Oncology}},
issue = {{6_suppl}},
pages = {{TPS603-TPS603}},
note = {{Accessed on 2025/07/22}}}